1. Medtech Insight
  2. >>Digital Technologies

LSX Medtech Panelists Talk AI, Market Access Strategies, Digital Therapeutics Reimbursement

 
• By Marion Webb

Highlights from Medtech Insight's on-the-ground coverage of LSX in Boston. 

LSX World
• Source: Citeline

Medtech Insight is on the ground at the LSX World Congress USA, which brings together leaders from medtech, healthtech and biotech and investors with a focus on facilitating partnerships, investment and dealmaking.

About 1,000 attendees from across the globe flocked to Boston 11-12 September to explore new opportunities, network and learn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Medtech Insight

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.